The Full Wiki

More info on Rubitecan

Rubitecan: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Rubitecan
Systematic (IUPAC) name
(4S)-4-ethyl-4-hydroxy-11-nitro-1 H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4 H,12H)-dione
Identifiers
CAS number 91421-42-0
ATC code none
PubChem 11954380
Chemical data
Formula C 20H15N3O6  
Mol. mass 393.349 g/mol
Synonyms (19S)-19-ethyl-19-hydroxy-10-nitro-17-oxa-3,13-diazapentacyclo[11.8.0.0 2,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status
Routes Oral

Rubitecan (INN, marketing name Orathecin) is an oral topoisomerase inhibitor, developed by Supergen.

History

On January 27, 2004, Supergen announced that it has completed the submission of an NDA for rubitecan to the US FDA, [1] and was accepted for filing on March 2004.[2]

On January 2005, Supergen withdrew the NDA for rubitecan, based on feedback indicating that the current data package would not be sufficient to gain US approval,[3] and on January 2006, the Marketing Authorization Application (MAA) filed with the European Medicines Agency (EMA) was also withdrawn.[4]

References








Got something to say? Make a comment.
Your name
Your email address
Message